Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has a cash flow conversion efficiency ratio of 0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥9.12 Million ≈ $1.33 Million USD) by net assets (CN¥910.35 Million ≈ $133.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) net asset quality to measure how much of total assets are equity-financed.
Shenzhen Bioeasy Biotechnology Co. Ltd. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Shenzhen Bioeasy Biotechnology Co. Ltd. to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Bioeasy Biotechnology Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Bioeasy Biotechnology Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Trendzone Decor Grp
SHG:603030
|
0.052x |
|
Tarczynski S.A.
WAR:TAR
|
0.055x |
|
Beijing HuaYuanYiTong Thermal Technology Co Ltd
SHE:002893
|
0.076x |
|
Siamgas and Petrochemicals Public Company Limited
BK:SGP-R
|
0.054x |
|
Swedencare publ AB
ST:SECARE
|
0.007x |
|
BTS Group AB (publ)
ST:BTS-B
|
-0.001x |
|
Lingsen Precision Industries Ltd
TW:2369
|
0.034x |
|
Mobia Medical, Inc. Common Stock
NASDAQ:MOBI
|
0.106x |
Annual Cash Flow Conversion Efficiency for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Shenzhen Bioeasy Biotechnology Co. Ltd..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥907.68 Million ≈ $132.82 Million |
CN¥66.87 Million ≈ $9.79 Million |
0.074x | +87.15% |
| 2024-12-31 | CN¥870.24 Million ≈ $127.34 Million |
CN¥34.26 Million ≈ $5.01 Million |
0.039x | +189.70% |
| 2023-12-31 | CN¥848.73 Million ≈ $124.20 Million |
CN¥-37.25 Million ≈ $-5.45 Million |
-0.044x | -127.75% |
| 2022-12-31 | CN¥964.70 Million ≈ $141.17 Million |
CN¥152.55 Million ≈ $22.32 Million |
0.158x | -41.40% |
| 2021-12-31 | CN¥946.58 Million ≈ $138.51 Million |
CN¥255.42 Million ≈ $37.38 Million |
0.270x | +132.21% |
| 2020-12-31 | CN¥548.98 Million ≈ $80.33 Million |
CN¥63.79 Million ≈ $9.34 Million |
0.116x | -8.70% |
| 2019-12-31 | CN¥528.32 Million ≈ $77.31 Million |
CN¥67.24 Million ≈ $9.84 Million |
0.127x | -51.09% |
| 2018-12-31 | CN¥222.62 Million ≈ $32.58 Million |
CN¥57.93 Million ≈ $8.48 Million |
0.260x | +26.35% |
| 2017-12-31 | CN¥114.60 Million ≈ $16.77 Million |
CN¥23.60 Million ≈ $3.45 Million |
0.206x | -68.67% |
| 2016-12-31 | CN¥55.24 Million ≈ $8.08 Million |
CN¥36.31 Million ≈ $5.31 Million |
0.657x | -- |
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more